Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Re:NewCell in connection with a directed share issue (2)
Mandate

Vinge has advised Re:NewCell in connection with a directed share issue

June 30, 2023 Capital Markets and Public M&A

Vinge has advised Re:NewCell, a textile-to-textile recycling company listed on Nasdaq First North Premier Growth Market, in connection with a directed share issue whereby the company raised proceeds of approximately SEK 240 million before issue costs.

The share issue was directed to a number of selected Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Founded by innovators from Stockholm’s KTH Royal Institute of Technology in 2012, Re:NewCell AB (publ) is a multi-award-winning sustaintech company based in Sweden. The company’s vision is to make fashion circular.

Vinge’s team consisted of Dain Hård Nevonen, William Kåge and Annie Fällström.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026